16 research outputs found
MING-WOOD LIU, Madhyamaka Thought in China, Sinica Leidensia, Volume XXX. Leiden: E.J. Brill, 1994. 288 pp. Notes, Bibliographical References, Index.
Lambert Schmithausen, Der Nirvāṇa-Absehnitt in der Viniścayasaṃgrahaṇi der Yogācārabhumiḥ.
Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients
Tumour-infiltrating lymphocytes (TILs) are considered to have prognostic and predictive value for patients with early breast cancer. We examined 1166 breast cancer patients from a prospective, multicentre cohort (Prognostic Assessment in Routine Application (PiA), n = 1270, NCT 01592825) following recommendations from the International TILs Working Group. TIL quantification was performed using predefined groups and as a continuous variable in 10% increments. The primary objective was the distribution of TILs in different breast cancer types. The second objective was the association with the recurrence-free interval (RFI) and overall survival (OS). Stromal infiltration with more than 60% TILs appeared in 2% of hormone receptor (HR)-positive and HER2-negative tumours, in 9.8% of HER2-positive tumours (any HR) and 19.4% of triple-negative breast cancers (TNBCs). Each 10% increment was associated with an improvement in the prognosis in HER2-positive samples (RFI, hazard ratio 0.773, 95% CI 0.587–1.017; OS, hazard ratio 0.700, 95% CI 0.523–0.937). When defining exploratory cut-offs for TILs, the use of a 30% threshold for the HR-positive and HER2-negative group, a 20% threshold for the HER2 group and a 60% threshold for the TNBC group appeared to be the most suitable. TILs bore prognostic value, especially in HER2-positive breast cancer. For clinical use, additional research on the components of immune infiltration might be reasonable
Additional file 3: Table S1. of Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors
Relationship between clusters and clinical and pathological characteristics. (XLS 36 kb
Additional file 5: Table S3. of Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors
Correlation between key target expression and patients and tumor characteristics. (XLS 46 kb
Additional file 8: Table S6. of Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors
RPPA data expression matrix with matched clinical data. (XLS 749 kb